Akutní myeloidní leukemie
- doc. MUDr. Petr Cetkovský, Ph.D., Ústav hematologie a krevní transfuze, Praha
- prof. MUDr. Jan Starý, DrSc., Klinika dětské hematologie a onkologie, FN v Motole, Praha
- prof. MUDr. Jiří Mayer, CSc., Interní hematoonkologická klinika FN Brno, Brno
How I treat leukemia during pregnancy
Otevřít | 2014 | MUDr. Zuzana Šustková
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival
Otevřít | 2013 | MUDr. Lukáš Semerád
Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making
Otevřít | 2013 | MUDr. Zuzana Šustková
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial
Otevřít | 2013 | MUDr. Zuzana Šustková
Effect of gentuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomized, open-label, phase 3 study
Otevřít | 2012 | MUDr. Zuzana Šustková
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Otevřít | 2012 | MUDr. Zuzana Šustková
Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia
Otevřít | 2012 | MUDr. Zuzana Šustková
Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European organisation for research and treatment of cancer Leukemia group and the German MDS study group
Otevřít | 2011 | MUDr. Marie Langová
Autologous peripheral blood stem cell transplantation for acute myeloid leukemia
Otevřít | 2011 | MUDr. Zuzana Šustková
A randomized trial comparing standard versus high-dose daunorubicin induction in pacients with acute myeloid leukemia
Otevřít | 2011 | MUDr. Zuzana Šustková
Clinical management of primary nonacute promyelocytic leukemia acute myeloid leukemia: practice guidelines by the Italian society of hematology, the Italian society of experimental hematology and the Italian group for bone marrow transplantation
Otevřít | 2009 | MUDr. František Folber
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Otevřít | 2009 | MUDr. František Folber
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients
Otevřít | 2009 | MUDr. František Folber
Anthracycline dose intensification in acute myeloid leukemia
Otevřít | 2009 | MUDr. Martina Tošková
High-dose daunorubicin in older patients with acute myeloid leukemia
Otevřít | 2009 | MUDr. Martina Tošková
Daunorubicine versus mitoxantrone versus idarubicine as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA groups study AML-10
Otevřít | 2009 | MUDr. Martina Tošková
Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML 11 a LRF AML 14 trials
Otevřít | 2009 | MUDr. Zuzana Šustková
Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-Vvrsus-host disease is the strongest factor improving survival
Otevřít | 2008 | MUDr. František Folber
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Otevřít | 2008 | MUDr. František Folber
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome
Otevřít | 2008 | MUDr. František Folber
Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia
Otevřít | 2008 | MUDr. František Folber
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results
Otevřít | 2008 | MUDr. František Folber
The significance of minimal residual disease kinetics in adults with newly diagnosed PML-RARα-positive acute promyelocytic leukemia: results of a prospective trial.
Otevřít | 2008 | MUDr. Zdeněk Kořístek
Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype
Otevřít | 2008 | MUDr. Zuzana Šustková
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
Otevřít | 2007 | MUDr. František Folber
Effect of consolidation with arsenic trioxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710
Otevřít | 2007 | MUDr. Zdeněk Kořístek